Array BioPharma

Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.

Array BioPharma

Company type	Subsidiary of Pfizer
Industry	Oncology Medication
Founded	1998; 26 years ago (1998)
Founder	Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou
Headquarters	Boulder, Colorado , United States of America
Revenue	$173.8 million (2018)
Parent	Pfizer
Website	www.arraybiopharma.com

History

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.^[1]

In November 2000, the company became a public company via an initial public offering.^[2]

In June 2019, Pfizer acquired the company for approximately $11 billion.^[3]

Discovery of FDA Approved Small Molecules

• MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer
• TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics)
• BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer
• KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics
• KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca
• VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly)

References

1. "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
2. "Array IPO up 17%". CNN. November 17, 2000.
3. "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. 18 June 2019. Retrieved 2020-07-29.